Announcement • Jul 31
Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 2.75 million. Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 2.75 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 55,000,000
Price\Range: AUD 0.05
Discount Per Security: AUD 0.003
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Announcement • Jul 04
Nasdaq to Delist ADS of Advanced Health Intelligence The Nasdaq Stock Market announced that it will delist the American Depositary Shares of Advanced Health Intelligence Ltd. Advanced Health Intelligence’s security was suspended on July 30, 2024 and has not traded on Nasdaq since that time. Announcement • Dec 02
Advanced Health Intelligence Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.272075 million. Advanced Health Intelligence Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.272075 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 22,222,222
Price\Range: AUD 0.0675
Discount Per Security: AUD 0.00405
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,284,441
Price\Range: AUD 0.0675
Discount Per Security: AUD 0.00405
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,153,701
Price\Range: AUD 0.0675
Discount Per Security: AUD 0.00405
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Announcement • Oct 30
Advanced Health Intelligence Ltd, Annual General Meeting, Nov 29, 2024 Advanced Health Intelligence Ltd, Annual General Meeting, Nov 29, 2024. Location: at steinepreis paganin, level 14, qv1, 250 st george`s terrace, perth wa 6000 Australia Announcement • Jul 30
Advanced Health Intelligence Ltd(NasdaqCM:AHI) dropped from NASDAQ Composite Index AHI has been dropped from NASDAQ Composite Index Announcement • Apr 16
Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million. Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 29,000,000
Price\Range: AUD 0.0675
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Announcement • Feb 27
Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,000,000
Price\Range: AUD 0.1
Transaction Features: Subsequent Direct Listing Announcement • Dec 02
Advanced Health Intelligence Ltd to Launch Medically Approved Mobile Phone-Based Atrial Fibrillation Assessment Advanced Health Intelligence Ltd. announced that the Company will be expanding the current biometric assessment suite with on-mobile device Atrial Fibrillation (AF) service in quarter 2 of 2024 after signing a binding agreement with QOMPIUM NV. AHI is thrilled to be expanding the biometric capabilities the company is bringing to the global healthcare system with the introduction of AF-Scan. This ground-breaking mobile phone-based solution is set to revolutionise the detection and management of Atrial Fibrillation (AF). This innovative technology is poised to offer unprecedented accessibility and convenience, opening new possibilities in AF monitoring for global populations. With the increasing prevalence of AF and its substantial impact on healthcare systems and economies, AF-Scan will emerge as a critical tool for individuals, healthcare professionals, and public health initiatives. With widespread Approval and Accessibility, Qompium technology has received approval as software as a medical device in multiple countries, including Australia, the European Union (EU), the United Kingdom (UK), the United Arab Emirates (UAE), Saudi Arabia, Singapore, and the United States by the Food and Drug Administration (FDA). This extensive approval further underscores the reliability and credibility of assisting with AF detection and is a unique and sought-after addition to the AHI biometric assessment offering. Atrial Fibrillation (af) is a prevalent cardiac condition with a substantial impact on public health. AHI's BHA harnesses the power of PPG collected via the flashlight and camera on smartphone to provide downstream services such as AF-Scan with the necessary biometric signals. The solution is backed by a medically certified AI algorithm that swiftly analyses the PPG measurements it captures. This analysis generates a comprehensive set of graphical data in the form of a report to be consumed by a physician. One can share this report with physician, making discussions about heart health more productive. AF diagnosis is challenging, often leading to underdiagnosis and misdiagnosis, emphasizing the need for proactive monitoring. AF-Scan is a mobile phone-based solution addressing these challenges. It offers accessibility and convenience, bridging gaps in AF monitoring worldwide. By empowering individuals to monitor their heartythm, AF-Scan aims to reduce the incidence of complications like strokes and heart failure, optimising healthcare spending. This level of accessibility can potentially transform how approach cardiac health. AI will incorporate the AF-Scan into biometric health assessment platform. This integration will further enhance the sensor sets already used across multiple disease categories, encompassing a remarkable 41 intrinsic biomarkers. This synergy will provide individuals with a comprehensive health assessment that goes beyond cardiac health, allowing to offer a holistic view of their well-being. AF-Scan offers a game-changing alternative in a market where traditional AF screening and monitoring methods often involve cumbersome processes and visits to healthcare facilities. By combining the mobile phone with advanced biometric health assessment platform, provide individuals with a powerful tool that empowers them to take control of their health like never before. As the roll out AF-Scan and integrate it into existing platform, are not just launching a product but pioneering a product but pioneering a product. Announcement • Nov 06
Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million. Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 10,749,996
Price\Range: AUD 0.11
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 9,245,454
Price\Range: AUD 0.11
Transaction Features: Subsequent Direct Listing Announcement • Nov 01
Advanced Health Intelligence Ltd. announced delayed 20-F filing On 10/31/2023, Advanced Health Intelligence Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Announcement • Oct 19
Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023 Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023, at 10:30 W. Australia Standard Time. Location: Steinepreis Paganin, Level 4, 16 Milligan Street, Perth WA 6000 Perth Western Australia Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2023 together with the declaration of the Directors, the Director's report, the Remuneration Report and the auditor's report; to consider adoption of remuneration report; to election of director Jacqueline yee; to re-election of director Dato low koon poh; to re-election of director Mike melby; to issue of shares to related party Nicholas prosser; to issue of shares to related party Mike melby; to approval of 7.1A mandate; to adoption of employee securities incentive plan; to ratification of prior issue of lender shares; to ratification of prior issue of consultant shares; to ratification of prior issue of supplier shares; to ratification of prior issue of placement shares listing rule 7.1; to ratification of prior issue of placement shares listing rule 7.1A; to ratification of prior issue of lead manager options; and to consider other issues. Announcement • Sep 14
Advanced Health Intelligence Ltd. announced that it has received AUD 1.5 million in funding Advanced Health Intelligence Ltd. announced a private placement of unsecured convertible loan facility for the gross proceeds of AUD 1,500,000 on September 12, 2023. The loan carry interest rate of 10% per annum and is compounded quarterly in arrears and will mature after 24 months from the date of signing. The investors may elect to redeem the outstanding principal amount and interest on the loans in cash on the Maturity Date. The loans and interest may be converted into fully paid ordinary shares at the investor’s election, at a conversion price equal to AUD 0.30 per share. The transaction is subject to shareholders approval. Announcement • Jun 15
Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million. Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 20,000,000
Price\Range: AUD 0.25
Discount Per Security: AUD 0.015
Transaction Features: Subsequent Direct Listing 
